Carregant...
RAS and BRAF in metastatic colorectal cancer management
The treatment of metastatic colorectal cancer (mCRC) has been further refined with the development of monoclonal antibodies, cetuximab and panitumumab, towards the epidermal growth factor receptor (EGFR). Anti-EGFR therapy has afforded improved survival in those with wild-type RAS mCRC but provides...
Guardat en:
Publicat a: | J Gastrointest Oncol |
---|---|
Autors principals: | , , |
Format: | Artigo |
Idioma: | Inglês |
Publicat: |
AME Publishing Company
2016
|
Matèries: | |
Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5056249/ https://ncbi.nlm.nih.gov/pubmed/27747083 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21037/jgo.2016.06.12 |
Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|